IBSA Derma

IBSA Derma is the aesthetic medicine division of IBSA (Institut Biochimique SA), a Swiss multinational pharmaceutical company. The company specializes in the development and production of hyaluronic acid-based dermo-aesthetic treatments, leveraging its proprietary NAHYCO Hybrid Technology. Its flagship product, Profhilo, is a market-leading bioremodeling injectable used for treating skin laxity and improving skin quality. IBSA Derma maintains a fully integrated supply chain, controlling the entire process from the biofermentation of raw materials to the finished medical devices. The company's portfolio also includes the Aliaxin line of dermal fillers and Viscoderm skin enhancers, positioning it as a key player in the global regenerative aesthetics market.